Cancer Family
Hematopoietic and Lymphatic System Neoplasm
CI-CAN-00000022Explore in graph →
Non-malignant4,304 active trials98 approved drugs1,010 evidence items
- NCIt
- C35813
Loading cancer entity…
Cancer Family
CI-CAN-00000022Explore in graph →
Clinical trials
18,827 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT07313852 | A Study of Inotuzumab and Blinatumomab in People With B-cell Acute Lymphoblastic Leukemia | not yet recruiting | Phase 1 / Phase 2 | 26 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Aug 11, 2026 | clinicaltrials |
| NCT07757412 | Teclistamab in Combination With Pomalidomide Administered in Alternative Fashion in Participants With Relapsed or Refractory Multiple Myeloma.(ADAPTATION) | not yet recruiting | Phase 2 | 50 | Odense University HospitalOTHER | 4 |
| Aug 11, 2026 |
| clinicaltrials |
| NCT07758218 | Allogeneic iNKT Cell Therapy (agenT-797) After SCT | not yet recruiting | Phase 1 | 22 | University of Wisconsin, MadisonOTHER | 1 | Aug 11, 2026 | clinicaltrials |
| NCT07758673 | Genetically Engineered Cells (BAFFR-CAR T Cells) for the Treatment of Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia and B-cell Lymphoblastic Lymphoma | not yet recruiting | Phase 1 | 16 | City of Hope Medical CenterOTHER | 1 | Aug 11, 2026 | clinicaltrials |
| NCT07009899 | BCMA Bispecific Antibody Therapy for Post-BCMA CAR T-Cell Therapy Relapse (RECLAIM)(RECLAIM) | not yet recruiting | Phase 2 | 34 | Medical College of WisconsinOTHER | 1 | Aug 10, 2026 | clinicaltrials |
| NCT07221032 | FT836 CAR T-cell Therapy in Combination With Daratumumab in Patients With Relapsed and/or Refractory Multiple Myeloma | not yet recruiting | Phase 1 | 12 | Medical College of WisconsinOTHER | 1 | Aug 10, 2026 | clinicaltrials |
| NCT07681258 | A Study of Asciminib Safety and Efficacy in Young Adults With Chronic Myeloid Leukemia in the Gulf Region(ASC4Young) | not yet recruiting | — | 80 | Novartis PharmaceuticalsINDUSTRY | 0 | Aug 10, 2026 | clinicaltrials |
| NCT07754682 | Immunoglobulin Replacement Therapy (IgRT) Versus Antibiotic Prophylaxis (PA) in Patients Treated by CD19-targeted Chimeric Antigen Receptor (CAR)T Cells for a B Cell Acute Lymphoblastic Leukemia or a B Cell Lymphoma(PREV-CART) | not yet recruiting | Phase 3 | 228 | Assistance Publique - Hôpitaux de ParisOTHER | 0 | Aug 10, 2026 | clinicaltrials |
| NCT07755202 | Gilteritinib-Azacitidine-Venetoclax Combination Therapy in Patients With Relapsed/Refractory Leukemia(GAVE001) | not yet recruiting | Phase 2 | 20 | Florian KuchenbauerOTHER | 1 | Aug 10, 2026 | clinicaltrials |
| NCT07751471 | BCMA/GPRC5D Trispecific Antibody Treatment for Newly Diagnosed Amyloidosis (AL-004)(AL-004) | not yet recruiting | Phase 2 | 20 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 1 | Aug 7, 2026 | clinicaltrials |
| NCT07751588 | Plasma ctDNA Monitoring in Pediatric Acute Leukemia | not yet recruiting | — | 25 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 1 | Aug 7, 2026 | clinicaltrials |
| NCT07752121 | First-Line Luspatercept in Transfusion-Dependent Lower-Risk Myelodysplastic Neoplasms(LUNIS) | not yet recruiting | — | 190 | Bristol-Myers SquibbINDUSTRY | 1 | Aug 7, 2026 | clinicaltrials |
| NCT07753148 | Safety and Tolerability of REGN17235 in Adult Participants With Clonal Cytopenia of Undetermined Significance and Low-Risk Myelodysplastic Syndrome With SF3B1 Mutation | not yet recruiting | Phase 1 | 52 | Regeneron PharmaceuticalsINDUSTRY | 0 | Aug 7, 2026 | clinicaltrials |
| NCT07518329 | Study of ALA-101 in Patients With CD19 Positive Non-Hodgkin Lymphoma and Leukemia.(SAPPHIRE) | not yet recruiting | Phase 1 | 46 | Arovella Therapeutics LtdINDUSTRY | 1 | Aug 6, 2026 | clinicaltrials |
| NCT07597590 | Digital Patient-Reported Assessment in Older Adults With Acute Leukemia | not yet recruiting | N/A | 20 | Fundación para la Investigación Biosanitaria del Principado de AsturiasOTHER | 1 | Aug 6, 2026 | clinicaltrials |
| NCT07743047 | Harnessing the Immunosuppressive Leukemic Microenvironment to Engineer T Cells With Enhanced Anti-tumor Functionality(SynT) | not yet recruiting | — | 65 | IRCCS San RaffaeleOTHER | 0 | Aug 6, 2026 | clinicaltrials |
| NCT07744724 | Pirtobrutinib+Pola-R-CHP for Newly Diagnosed Non-GCB DLBCL | not yet recruiting | Phase 2 | 48 | Changzhou No.2 People's HospitalOTHER | 1 | Aug 6, 2026 | clinicaltrials |
| NCT07744737 | Pirtobrutinib + R-CHOP for Untreated Non-GCB DLBCL | not yet recruiting | Phase 2 | 34 | Changzhou No.2 People's HospitalOTHER | 1 | Aug 6, 2026 | clinicaltrials |
| NCT07744750 | Pirtobrutinib+Sonrotoclax(PS) Regimen in the Treatment of B-Cell Lymphoma | not yet recruiting | Phase 2 | 40 | Changzhou No.2 People's HospitalOTHER | 1 | Aug 6, 2026 | clinicaltrials |
| NCT07748689 | Comparing Lower Versus Standard Doses of Belantamab Mafodotin With Pomalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma.(REBEL) | not yet recruiting | Phase 2 | 228 | Polish Myeloma ConsortiumOTHER | 0 | Aug 6, 2026 | clinicaltrials |
| NCT07749976 | GRACE: A Phase 1/2a Study of VTRU200 in Relapsed/Refractory AML, High-risk MDS, DLBCL Post CART Failure and Advanced Solid Tumors | not yet recruiting | Phase 1 / Phase 2 | 108 | VitruviaeINDUSTRY | 0 | Aug 6, 2026 | clinicaltrials |
| NCT07526597 | Study on Treatment Outcome Patterns for Patients With CLL After Discontinuation of BTK Inhibitors(STOP-CLL-DCT) | not yet recruiting | Phase 2 | 45 | UNC Lineberger Comprehensive Cancer CenterOTHER | 1 | Aug 5, 2026 | clinicaltrials |
| NCT07712588 | Birelentinib Plus R-CHOP in Patients With Newly Diagnosed Diffuse Large B-Cell Lymphoma (TAI-SHAN19) | not yet recruiting | Phase 2 / Phase 3 | 880 | Dizal PharmaceuticalsINDUSTRY | 1 | Aug 5, 2026 | clinicaltrials |
| NCT07740603 | Study of CD38 and CD56 in Chronic Myeloid Leukemia | not yet recruiting | — | 200 | Sohag UniversityOTHER | 0 | Aug 5, 2026 | clinicaltrials |
| NCT07746245 | The Efficacy of CAPCT in Patients With PTCL | not yet recruiting | Phase 2 | 58 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Aug 5, 2026 | clinicaltrials |
| NCT07748455 | HMA-Venetoclax Induction in Newly Diagnosed AML(VENTURE-AML) | not yet recruiting | Phase 2 | 60 | Pakistan Blood and Marrow Transplant (PBMT) GroupOTHER | 1 | Aug 5, 2026 | clinicaltrials |
| NCT07741695 | Targeting IRAK4 in Chronic Lymphocytic Leukemia(PS-CLL016) | not yet recruiting | — | 50 | IRCCS San RaffaeleOTHER | 0 | Aug 4, 2026 | clinicaltrials |
| NCT07742527 | A Study to Evaluate the Subcutaneous Belantamab (BCMAb) Formulation Versus Intravenous Belantamab in Participants With Multiple Myeloma While Treated With Standard of Care(DynaMMic-2) | not yet recruiting | Phase 1 | 22 | GlaxoSmithKlineINDUSTRY | 0 | Aug 3, 2026 | clinicaltrials |
| NCT07742891 | ReSeT in ALL 2: A Randomized, Controlled Pilot Trial Testing an Optimized, Multi-component Mobile Health Intervention to Reduce Sedentary Time in Early Adolescents and Young Adults (eAYAs) With ALL During Maintenance Therapy | not yet recruiting | N/A | 50 | Children's Hospital Los AngelesOTHER | 0 | Aug 3, 2026 | clinicaltrials |
| NCT07679334 | Phase I Trial of Pacritinib in Combination With Venetoclax and Azacitidine for the Treatment of Accelerated and Blast Phase Myeloproliferative Neoplasms | not yet recruiting | Phase 1 | 20 | Roswell Park Cancer InstituteOTHER | 1 | Jul 31, 2026 | clinicaltrials |
| NCT07737418 | Dyadic Physical Activity Intervention for Children Undergoing Cancer Treatment(DYAD-PA) | not yet recruiting | N/A | 198 | The Hong Kong Polytechnic UniversityOTHER | 0 | Jul 31, 2026 | clinicaltrials |
| NCT07738887 | Epcoritamab Plus Venetoclax Plus Ibrutinib in Patients With Chronic Lymphocytic Leukemia With TP53 Alterations(EVITA) | not yet recruiting | Phase 2 | 44 | The Lymphoma Academic Research OrganisationOTHER | 2 | Jul 31, 2026 | clinicaltrials |
| NCT07739849 | Flow on FNA/Core Project- Faster Diagnosis for Lymphoma: Utilising Flow Cytometry on FNA Samples of Lymph Nodes to Diagnose Lymphoma in Hours, Not Days.(Flow on FNA) | not yet recruiting | N/A | 200 | The Clatterbridge Cancer Centre NHS Foundation TrustOTHER | 0 | Jul 31, 2026 | clinicaltrials |
| NCT07740486 | A Study Comparing Treatment With Teclistamab and Talquetamab Versus Daratumumab and Lenalidomide in Patients With Multiple Myeloma After Stem Cell Transplant Who Still Have Detectable Disease(TiTan) | not yet recruiting | Phase 3 | 248 | Polish Myeloma ConsortiumOTHER | 0 | Jul 31, 2026 | clinicaltrials |
| NCT07072585 | Testing the Addition of Daratumumab to Chemotherapy for Treating Patients With Newly-Diagnosed T-Cell Lymphoblastic Leukemia (T-ALL) and T-Cell Lymphoblastic Lymphoma (T-LL) | not yet recruiting | Phase 2 / Phase 3 | 1,708 | Children's Oncology GroupNETWORK | 0 | Jul 30, 2026 | clinicaltrials |
| NCT07735637 | A Phase III, Multicentre Study to Evaluate Consolidation Treatment With AZD0120 Compared With ASCT, in Participants With Newly Diagnosed Multiple Myeloma Who Are Transplant Eligible (DURGA-6).(DURGA-6) | not yet recruiting | Phase 3 | 750 | AstraZenecaINDUSTRY | 15 | Jul 30, 2026 | clinicaltrials |
| NCT07737769 | Arsenic Trioxide to Prevent Relapse in Patients Undergoing Allogeneic Stem Cell Transplantation for Acute Myeloid Leukemia or Myelodysplastic Syndrome | not yet recruiting | Phase 1 | 20 | University of Michigan Rogel Cancer CenterOTHER | 1 | Jul 30, 2026 | clinicaltrials |
| NCT07459608 | Efficacy and Safety of Lisaftoclax (APG-2575) Monotherapy in Patients With Mature B-cell Lymphoma | not yet recruiting | Phase 2 | 75 | Henan Cancer HospitalOTHER_GOV | 1 | Jul 29, 2026 | clinicaltrials |
| NCT07732712 | Isa-VRdlite for of Frail and/or Much Older Patients With High Risk Newly Diagnosed Multiple Myeloma Base on Circulating Plasma Cells | not yet recruiting | Phase 2 / Phase 3 | 15 | The Affiliated People's Hospital of Ningbo UniversityOTHER_GOV | 0 | Jul 29, 2026 | clinicaltrials |
| NCT07733141 | Mindfulness Intervention to Reduce Patient Reported Symptoms in Patients With Chronic Graft-Versus-Host Disease | not yet recruiting | N/A | 17 | City of Hope Medical CenterOTHER | 1 | Jul 29, 2026 | clinicaltrials |
| NCT07734272 | Standardized Documentation and Assessments for Polycythemia Vera: A Quality Improvement Initiative(STANDARDIZE-PV) | not yet recruiting | N/A | 32 | Massachusetts General HospitalOTHER | 0 | Jul 29, 2026 | clinicaltrials |
| NCT07735117 | Mitoxantrone Hydrochloride Liposome, Cytarabine, G-CSF Plus Venetoclax vs. Azacitidine Plus Venetoclax for MDS-IB2 and Secondary/Elderly AML | not yet recruiting | Phase 3 | 168 | Ruijin HospitalOTHER | 0 | Jul 29, 2026 | clinicaltrials |
| NCT07735208 | Geriatric Assessment-Guided Treatment Selection in Older Adults With Acute Myeloid Leukemia(ALIGN-AML) | not yet recruiting | Phase 2 | 120 | University of RochesterOTHER | 1 | Jul 29, 2026 | clinicaltrials |
| NCT07717164 | PRAISE-IR Versus CIBMTR Controls | not yet recruiting | — | 51 | Miltenyi Biomedicine GmbHINDUSTRY | 1 | Jul 28, 2026 | clinicaltrials |
| NCT07621887 | Digitalized Exercise Fit Tool Intervention for Adolescents With Blood Cancer | not yet recruiting | N/A | 30 | The Hong Kong Polytechnic UniversityOTHER | 0 | Jul 27, 2026 | clinicaltrials |
| NCT07727668 | Iberdomide (CC-220) Priming to Improve T Cell Fitness Prior to Leukapheresis for Chimeric Antigen Receptor T Cell (CAR-T) Therapy for Relapsed/Refractory Multiple Myeloma (RRMM) | not yet recruiting | Early Phase 1 | 22 | Shambavi RichardOTHER | 1 | Jul 27, 2026 | clinicaltrials |
| NCT07728188 | A Study to Evaluate Adverse Events and Change in Disease Activity With Injected Etentamig Plus Oral Pomalidomide Versus Standard Therapies in Adults With Relapsed or Refractory Multiple Myeloma | not yet recruiting | Phase 3 | 520 | AbbVieINDUSTRY | 13 | Jul 27, 2026 | clinicaltrials |
| NCT07729397 | Autologous IC-Nine, CD30 CAR, and Constitutive IL7R Expressing EBVST for CD30 Lymphoma (ANCILE-30)(ANCILE-30) | not yet recruiting | Phase 1 | 21 | The Methodist Hospital Research InstituteOTHER | 1 | Jul 27, 2026 | clinicaltrials |
| NCT07374315 | Weight Gain in Pediatric Leukemia Survivors | not yet recruiting | N/A | 80 | Washington University School of MedicineOTHER | 1 | Jul 24, 2026 | clinicaltrials |
| NCT07724782 | Multi-Cohort Study of Zeprumetostat Combinations for Relapsed/Refractory PTCL | not yet recruiting | Phase 1 / Phase 2 | 33 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Jul 24, 2026 | clinicaltrials |
Data updated 23 days agoSource updated Aug 11, 2026source: clinicaltrials